Top 20 R&D Spending Biopharma Companies of 2026

Top 20 R&D Spending Biopharma Companies of 2026 Shots: Merck & Co., Roche, and Johnson & Johnson emerged as the leading pharmaceutical companies by R&D expenditure in 2025, investing $15.78B, $15.49B, and $14.66B, respectively. Continued investments in late-stage clinical programs, pipeline expansion, advanced technologies, and strategic business development reinforced their commitment to driving pharmaceutical innovation …

ByPrince Giri3 days ago

NEWS

AbCellera and Vertex Pharmaceuticals Team Up on T-Cell Engagers

Shots: AbCellera has entered into a collaboration with Vertex to research, develop, manufacture, & commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases & other conditions As per the deal, AbCellera will use its TCE platform for discovery & early development, while Vertex will fund all R&D costs and retain rights to develop & commercialize resulting…

ByRidhi Rastogi5 days ago

NEWS

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for ~$10B

Shots: Vertex has entered into a definitive agreement to acquire Crinetics, incl. its assets Palsonify (paltusotine) & atumelnant, accelerating Vertex’s revenue growth and enhancing its long-term earnings profile As per the deal, Vertex to acquire Crinetics for $85/share in cash, representing the total equity value of ~$10B, or ~$8.8B net of estimated cash acquired Palsonify (QD, PO)…

ByRidhi RastogiJuly 7, 2026

NEWS

Halozyme Licenses Hypercon Technology to Vertex for Convenient Drug Delivery

Shots: Halozyme Therapeutics, via its subsidiary Halozyme Hypercon, has entered a global exclusive collaboration & license agreement with Vertex to utilize its Hypercon technology across up to three drug targets As per the deal, Halozyme will receive $15M upfront, with additional milestone payments & royalties tied to products developed using the technology Hypercon is a…

ByRidhi RastogiApril 8, 2026

TOP 20

Top 20 Prescription Drugs of 2025

Shots: In 2025, the global Prescription Drugs market is projected to generate an impressive $1.13T, with steady annual growth of 3.94% expected through 2030, ultimately reaching $1.37T. Leading the pack is Keytruda, securing the first position with $29.48B, closely followed by Ozempic at $28.18B, and Eliquis, which recorded $20.69B in global sales. Fourth position is…

ByPrince GiriNovember 20, 2025

NEWS

Enlaza Therapeutics Collaborates with Vertex to Develop Drug Conjugates and T-Cell Engagers for Improved Conditioning and Autoimmune Diseases

Shots: Enlaza & Vertex’s muti-target collaboration will leverage Enlaza’s War-Lock platform to develop small format drug conjugates & T-cell engagers for autoimmune diseases & improved conditioning in sickle cell disease & β thalassemia Enlaza will receive $45M in upfront & equity investment & is eligible for >$2B in research, development, regulatory, & commercial milestones plus…

ByRidhi RastogiSeptember 3, 2025

NEWS

Vertex Reports the P-II Study of VX‑993 in Acute Pain After Bunionectomy

Shots: Vertex announced topline results from its P‑II study of selective NaV1.8 inhibitor VX‑993 in 367 pts with acute pain post-bunionectomy; VX‑993 did not achieve a statistically significant improvement in SPID48 vs placebo VX‑993 was safe and well tolerated at all doses, with AEs mostly mild/moderate; no SAEs related to VX‑993 and no discontinuations due…

ByPrince GiriAugust 7, 2025

NEWS

Vertex Receives the US FDA Approval for Journavx (Suzetrigine) to Treat Acute Pain

Shots: The FDA has approved Journavx (50mg; BID) to treat moderate-to-severe acute pain in adults JOURNAVX is an oral, non-opioid pain signal inhibitor that selectively targets NaV1.8 relative to other NaV channels The company is also testing suzetrigine for peripheral neuropathic pain (PNP), with ongoing P-III trial for diabetic neuropathy and plans for…

ByDipanshu DixitJanuary 30, 2025

NEWS

The US FDA Approves Vertex’s Alyftrek for the Treatment of Cystic Fibrosis

Shots: The US FDA has approved Alyftrek (QD, CFTR modulator) to treat patients (≥6yrs.) with cystic fibrosis (CF), having at least one F508del mutation or another CFTR gene mutation. Submissions are under review in the EU, UK, Canada, Switzerland, Australia & New Zealand Approval was supported by pivotal P-III CF program involving >1,000 patients across…

ByDipanshu DixitDecember 20, 2024

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2024

Shots: The second quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Vertex’ acquisition of Alpine Immune Sciences for ~$4.9B This quarter also showcased multiple clinical trial results including Moderna’s P-III Study Data of mRNA-1283 Vaccine to Prevent COVID-19…

BySenior EditorJuly 2, 2024

Top 20 R&D Spending Biopharma Companies of 2026

AbCellera and Vertex Pharmaceuticals Team Up on T-Cell Engagers

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for ~$10B

Halozyme Licenses Hypercon Technology to Vertex for Convenient Drug Delivery

Top 20 Prescription Drugs of 2025

Enlaza Therapeutics Collaborates with Vertex to Develop Drug Conjugates and T-Cell Engagers for Improved Conditioning and Autoimmune Diseases

Vertex Reports the P-II Study of VX‑993 in Acute Pain After Bunionectomy

Vertex Receives the US FDA Approval for Journavx (Suzetrigine) to Treat Acute Pain

The US FDA Approves Vertex’s Alyftrek for the Treatment of Cystic Fibrosis

PharmaShots’ Key Highlights of Second Quarter 2024

Contact US

FOLLOW US